Legal & General Group Plc Takes $2.17 Million Position in Dyne Therapeutics, Inc. $DYN

Key Points

• Legal & General Group Plc acquired 97,940 Dyne Therapeutics shares worth approximately $2.17 million, while institutional investors collectively own 96.68% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $34.42, despite one “Strong Sell” rating.
• Dyne reported a quarterly loss of $1.08 per share, missing expectations of a $0.75 loss, while insiders have sold roughly 4.14 million shares worth $99.45 million over the past 90 days.

Legal & General Group Plc purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 97,940 shares of the company's stock, valued at approximately $2,175,000. Legal & General Group Plc owned 0.05% of Dyne Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the first quarter valued at about $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth approximately $51,000. Allworth Financial LP purchased a new position in shares of Dyne Therapeutics in the second quarter worth approximately $62,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $84,000. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DYN. Sanford C. Bernstein raised their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research note on Wednesday, May 13th. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Royal Bank Of Canada raised their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday, July 30th. TD Cowen started coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a "buy" rating on the stock. Finally, Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $34.42.

Dyne Therapeutics Stock Performance

DYN stock opened at $24.28 on Friday. The firm has a 50 day simple moving average of $24.80 and a 200 day simple moving average of $20.36. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The stock has a market cap of $4.53 billion, a P/E ratio of -7.29 and a beta of 1.08. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jason Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the sale, the director owned 428,946 shares of the company's stock, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 4,139,196 shares of company stock worth $99,449,852. 9.46% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source